Compound Physician required WADA prohibited

Tesamorelin

FDA-approved GHRH analog that reduces visceral fat — explored off-label for body composition.

Approved Verified 27 August 2026

The story

Tesamorelin is one of the few compounds in this batch whose history is a conventional drug-development history, with a sponsor, a regulatory file, and a marketed product at the end of it.

The parent molecule came first. In 1982, Roger Guillemin's group at the Salk Institute isolated a growth hormone-releasing factor from a human pancreatic tumor that had caused acromegaly in its host — a natural experiment in which a tumor secreted enough of the hypothalamic releasing hormone to drive the pituitary continuously (Science, 1982; PMID 6812220). The active species was a 44-amino-acid amidated peptide, hGRF(1-44)NH₂. Its therapeutic problem was immediately obvious: dipeptidyl peptidase-IV cleaves native GHRH within minutes, which is why the endogenous hormone works as a pulse generator and why the unmodified peptide makes a poor drug. Sermorelin, the truncated GHRH(1-29) fragment, was the first commercial answer and had faded from the US market by the 2000s.

Theratechnologies, a Montreal biotechnology company, took a different approach: keep the full 44-residue sequence and armor the N-terminus. Their candidate, TH9507, attached a trans-3-hexenoyl moiety — a six-carbon chain with a double bond at position 3 — to the tyrosine at position 1. The published non-clinical work reported that this modification made the peptide resistant to DPP-IV deactivation, slowed its degradation in rat, dog and human plasma, and prolonged plasma elimination, while leaving it a GHRH-receptor agonist with potency comparable to the endogenous hormone. The same paper is candid about the cost of the modification: dogs given repeat daily subcutaneous injections showed reversible liver and kidney findings, anemia and organ-weight changes, which the authors attributed to "sustained exposure to supraphysiological levels of growth hormone and IGF-1" (DOI 10.1111/j.1742-7843.2007.00008.x).

The indication it was developed for was specific and, at the time, urgent. Antiretroviral therapy in the late 1990s and 2000s was associated with a redistribution of body fat — visceral adipose tissue accumulating in the abdomen while subcutaneous fat wasted — with metabolic and cardiovascular consequences and considerable distress about appearance. Recombinant human growth hormone worked on the fat but pushed patients toward insulin resistance. The GHRH-analog bet was that stimulating the pituitary to release its own GH in pulses, under intact negative feedback, would reduce visceral fat without the glucose penalty of exogenous GH.

The trial arc bore that out and is unusually clean. A 12-week, placebo-controlled, dose-ranging phase 2 in 61 patients compared two once-daily subcutaneous dose levels against placebo and established the regimen that was later approved (PMID 16052083). Two multicenter, randomized, double-blind, placebo-controlled phase 3 trials followed — 412 patients (NCT00123253, published in the New England Journal of Medicine in 2007) and 404 patients (NCT00435136, published in 2010) — each with a 26-week blinded extension in which patients were re-randomized to continue or stop. The primary endpoint in both was percent change in visceral adipose tissue measured by CT at the L4–L5 vertebral level. Both hit it, and the extension design answered the durability question directly: the reduction held to 52 weeks on drug and reversed when the drug stopped.

FDA's Endocrinologic and Metabolic Drugs Advisory Committee endorsed the application, and FDA approved EGRIFTA on 2010-11-10 under application 022505, with postmarketing requirements including a diabetic-retinopathy trial and a long-term observational safety study (Drugs@FDA; Medscape, 2010). EMD Serono launched it in the US; Theratechnologies regained US marketing rights in December 2013 (Theratechnologies, 2013-12-13). The application was deemed a Biologics License Application on 2020-03-23 under the statutory transition of protein products. Two reformulations followed, each reducing handling burden rather than changing the molecule: EGRIFTA SV in 2019 and EGRIFTA WR (tesamorelin F8) on 2025-03-25, which cut reconstitution from daily to weekly and more than halved the injection volume (Theratechnologies, 2025-03-25).

The route into longevity and fitness culture ran through the academic literature rather than through forums. Steven Grinspoon's group at Massachusetts General Hospital, which had co-authored the pivotal HIV work, extended the question outward: a 12-month randomized trial in non-HIV abdominally obese adults with reduced GH secretion (PMID 23015655), a two-week pulsatility and insulin-clamp study in healthy men (PMID 20943777), and a randomized trial of liver fat in HIV-associated NAFLD (Lancet HIV, 2019). Separately, Laura Baker's group at the University of Washington ran a 20-week randomized, placebo-controlled trial of tesamorelin for cognition in older adults with and without mild cognitive impairment (Archives of Neurology, 2012). Those papers — real trials, in populations without HIV — are what wellness clinics now cite when they market tesamorelin as "the visceral fat peptide." A 2026 narrative review of GH-axis performance peptides places tesamorelin at the top of its evidence tiers precisely because it has "regulatory-grade randomized trial data" that the rest of the class does not (DOI 10.3389/fendo.2026.1822475).

  1. 1982 Human growth hormone-releasing factor isolated from a pancreatic tumor that had caused acromegaly; hGRF(1-44)NH₂ characterized
  2. 2004–2007 TH9507 non-clinical program published: trans-3-hexenoyl modification at Tyr¹ confers DPP-IV resistance; dose-related GH and IGF-1 rises in rats, dogs and pigs
  3. 2005 Phase 2 dose-ranging trial (n=61, 12 weeks, placebo versus two once-daily subcutaneous dose levels) establishes the regimen later approved and shows IGF-1 rising without glucose change
  4. 2007 First phase 3 trial published in NEJM: n=412, VAT −15.2% vs +5.0% on placebo at 26 weeks
  5. 2008 52-week extension published: VAT reduction sustained at −18%, and VAT re-accumulates on discontinuation
  6. 2010 Second phase 3 trial (n=404) and the pooled 806-patient phase 3 analysis published
  7. 2010-11-10 FDA approves EGRIFTA (application 022505) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy
  8. 2012 Two randomized trials extend the question beyond HIV: 12-month trial in non-HIV abdominal obesity with reduced GH, and a 20-week cognition trial in older adults with and without MCI
  9. 2013-12 Theratechnologies regains US marketing rights from EMD Serono
  10. 2014 JAMA trial (n=50) shows tesamorelin reduces liver fat as well as visceral fat — the first ectopic-fat result
  11. 2019 EGRIFTA SV approved (single-vial formulation); Lancet HIV NAFLD trial published (n=61, 12 months)
  12. 2020-03-23 Application 022505 deemed a Biologics License Application under the statutory protein-product transition
  13. 2021 Anti-doping method paper reports that GHRH analogs — tesamorelin named — had not been found in WADA-accredited laboratory samples despite intelligence of use
  14. 2025-03-25 EGRIFTA WR (tesamorelin F8) approved: once-daily subcutaneous administration, weekly reconstitution, room-temperature storage (the label regimen is in). The sponsor states it will replace EGRIFTA SV — per sponsor announcement; that is a commercial intention, not an FDA action, and no withdrawal of the SV label has been recorded in a regulator document
  15. 2026 Two independent meta-analyses of the randomized tesamorelin literature published within months of each other

What it does

An FDA-approved GHRH analog that reduces visceral fat in its approved indication — the strongest human data any GH secretagogue in this category has. Body-composition/longevity use is off-label extrapolation.

A GHRH analog that stimulates the pituitary to release GH in its normal pulsatile pattern, raising IGF-1 and reducing visceral adipose tissue.

  • visceral fat
  • IGF-1

What the evidence shows

Tesamorelin works, and it is one of the two best-evidenced compounds in this batch: FDA-approved on 2010-11-10 under application 022505 (an NDA later deemed a BLA) on two replicated, multicenter, randomized, double-blind, placebo-controlled phase 3 trials totalling 806 randomized patients with 26-week blinded extensions, preceded by a 61-patient dose-ranging phase 2, whose CT-imaged primary endpoint it hit twice, with a visceral-fat reduction of roughly 15% that two independent 2026 meta-analyses confirm, that subcutaneous fat and body weight do not share, and that reverses when treatment stops. The limitation is population, not quality. Every pivotal trial enrolled people with HIV-associated lipodystrophy, and the randomized off-label literature beyond the label — a 12-month RCT in non-HIV abdominal obesity (n=60), a 12-month RCT in HIV-associated NAFLD (n=61) and a 20-week RCT in cognition (n=152) — reaches only people with established abdominal obesity and reduced GH secretion or with age-related cognitive concern, so no randomized trial has ever enrolled a healthy adult with normal GH secretion for body recomposition, which is precisely the use that drives off-label interest in it; nor has any trial been powered for cardiovascular outcomes or long-term malignancy risk. One conflict inside the approved evidence base is unresolved and stays on the record: the phase 3 papers report no significant glycemic difference, while the FDA label drawn from the same programme reports 5% versus 1% of patients crossing HbA1c ≥6.5%, a hazard ratio of 3.3 (95% CI 1.4–9.6), and carries glucose intolerance as a Warning.

Overall evidence strength: Moderate certainty

  • The phase 3 registration program (2007–2010) Randomized controlled trial

    In two separate trials of the same design, six months of a daily injection shrank the deep abdominal fat around the organs by roughly 15% while leaving the fat under the skin alone, and cut triglycerides — but it did this in people whose fat had been redistributed by HIV medication, it did not reduce body weight, and when the drug was stopped in the extension phase the visceral fat came back.

    Source PMID 18057338

  • Clemmons DR, Miller S, Mamputu JC (2017) — type 2 diabetes safety trial (2017) Randomized controlled trial

    The trial that tested the class's biggest theoretical objection head-on — that raising growth hormone should worsen diabetes — found no change in insulin response, fasting glucose, HbA1c or overall diabetes control over 12 weeks, and nobody dropped out for loss of diabetes control. Twelve weeks is short, 53 people is small, and this is a negative-safety finding rather than a demonstration that the drug is safe in diabetes indefinitely.

    Source PMID 28617838

  • Stanley TL, Feldpausch MN, Oh J, et al. (2014) — visceral fat and liver fat (2014) Randomized controlled trial

    The first trial to show that the fat tesamorelin removes is not only the fat around the organs but also fat inside the liver — a net −2.9% in liver lipid-to-water percentage — and also the first to catch a transient glucose signal, with fasting glucose up 7 mg/dL versus placebo at two weeks that was no longer significant at six months.

    Source PMID 25038357

  • Stanley TL, Fourman LT, Feldpausch MN, et al. (2019) — NAFLD, 12 months (2019) Randomized controlled trial

    Over a full year, liver fat fell by an absolute 4.1 percentage points more than placebo — a 37% relative reduction — and 35% of people on tesamorelin got their liver fat below the 5% threshold that defines fatty liver, versus 4% on placebo. Fasting glucose and HbA1c were no different between groups at 12 months. This is the strongest off-label result in the file, and it is still confined to people with HIV.

    Source PMID 31611038

  • Makimura H, Feldpausch MN, Rope AM, et al. (2012) — non-HIV abdominal obesity, 12 months (2012) Randomized controlled trial

    This is the one trial that most closely resembles the person tesamorelin is now marketed to, and it is positive but narrow: over a year, visceral fat fell (treatment effect −35 cm²), carotid intima-media thickness fell slightly, CRP and triglycerides improved, subcutaneous fat did not change, and glucose measures did not worsen. Participants had to have documented low GH secretion to enroll — it is not a study of metabolically ordinary people who want a flatter stomach.

    Source PMID 23015655

  • Baker LD, Barsness SM, Borson S, et al. (2012) — cognition (2012) Randomized controlled trial

    Twenty weeks of tesamorelin produced a small but statistically favorable effect on cognition overall (P=.03 intent-to-treat), driven mainly by executive function (P=.005), in both healthy older adults and people with mild cognitive impairment — but it also raised fasting insulin by 35% within the normal range in the MCI group, and no trial has since shown this translates into anything a person would notice or into a change in disease course.

    Source PMID 22869065

  • The 2026 meta-analyses

    Two independent groups pooled the randomized literature within months of each other, which is itself a marker of how much randomized data exists.

    Source PMID 41545261

What studies used — not a recommendation.

  • HIV with excess abdominal fat — dose-ranging phase 2 (n=61) within the FDA-approved indication · Placebo, 1 mg, or 2 mg subcutaneously once daily · 12 weeks PMID 16052083
  • HIV-associated lipodystrophy — phase 3 registration program (n=412 and n=404), the trials the approval rests on · 2 mg subcutaneously once daily, abdominal injection · 26 weeks, then a 26-week re-randomized extension (52 weeks total)
  • HIV-infected adults with lipodystrophy — current FDA labeling, EGRIFTA WR (11.6 mg/vial); the label regimen for the approved indication · 1.28 mg subcutaneously once daily, abdominal injection · Indefinite; label directs reconsidering continuation in patients without VAT reduction
  • HIV-infected adults with lipodystrophy — prior FDA labeling, EGRIFTA SV (2 mg/vial). The sponsor states this presentation is being transitioned to EGRIFTA WR (per sponsor announcement; no FDA withdrawal recorded) · 2 mg subcutaneously once daily. Labeling states the two formulations "are not substitutable" · Indefinite

Common misconceptions

“Tesamorelin is FDA-approved for visceral fat, so it's proven for anyone carrying belly fat.”

The approval is real and narrow. The indication is "reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy," and the same label carries an explicit Limitations of Use section stating that tesamorelin "is not indicated for weight loss management as it has a weight neutral effect" and that "long-term cardiovascular safety has not been established" (DailyMed — EGRIFTA WR). The label's own phase 3 data back the weight-neutral claim precisely: mean weight change at 26 weeks was −0.4 kg in Study 1 and +0.5 kg in Study 2, both non-significant against placebo, while visceral adipose tissue fell 18% and 14%. Outside HIV, the evidence is one 12-month randomized trial in 60 abdominally obese adults, and enrollment required documented reduced GH secretion — VAT fell by a treatment effect of −35 cm², carotid intima-media thickness and CRP improved, subcutaneous fat did not change (DOI 10.1210/jc.2012-2794). That is a genuine, positive, non-HIV randomized result, and it is a long way from "proven for anyone." Clinic marketing routinely closes that gap by implication rather than by claim. One clinic page states that tesamorelin "helps with weight loss by specifically targeting visceral abdominal fat through FDA-approved growth hormone stimulation" and that the therapy "works best for adults struggling with stubborn visceral fat that resists traditional diet and exercise" (Formation Medical, cited as evidence of what is claimed, not of what is true) — a sentence in which "FDA-approved" and "weight loss" appear together although the label says the drug is not indicated for weight loss. To be fair to the market, not all of it does this: another widely circulated page states plainly that "long-term safety data outside the HIV population remain incomplete" (Evergreen Institute). Honest answer: Tesamorelin reliably and reproducibly reduces visceral adipose tissue. Whether it does so in a metabolically ordinary adult with normal GH secretion, and whether that reduction translates into any health outcome in such a person, has never been tested. Both the enthusiasts and the dismissers are ahead of the data.

“It's the growth-hormone drug that doesn't mess with your blood sugar.”

This is the compound's second-biggest claim, it is half right, and the two authoritative sources disagree about the other half. ⚠️ Unresolved conflict between the published trials and the FDA label. The phase 3 papers report "no significant differences were observed in glycemic measures" (NEJM 2007), "no change in glucose parameters was observed" (JAIDS 2010), and "no clinically meaningful differences… in glucose parameters at wk 26 and 52" (JCEM 2010 pooled). The current FDA label, drawing on the same program, states that "patients receiving EGRIFTA had an increased risk of developing diabetes (HbA1c level ≥ 6.5%) compared with placebo (5% vs. 1%), with a hazard ratio of 3.3 (CI 1.4, 9.6)," carries Glucose Intolerance or Diabetes Mellitus as a Warning, and directs that glucose be evaluated before and periodically during therapy (DailyMed). Both statements are accurate about what they measure — mean glucose values did not shift, while the proportion crossing a diagnostic threshold did — and we do not resolve them. The practical reading is that group means are reassuring and individual risk is not. The rest of the picture is genuinely favorable and worth stating with equal directness. A euglycemic hyperinsulinemic clamp study in healthy men found insulin-stimulated glucose uptake preserved despite IGF-1 rising 181 µg/L (DOI 10.1210/jc.2010-1587). A dedicated 12-week randomized trial in 53 people with established type 2 diabetes found no change in insulin response, fasting glucose, HbA1c or diabetes control (DOI 10.1371/journal.pone.0179538). The 12-month NAFLD trial used glucose as its primary safety endpoint and found no between-group difference at 12 months (DOI 10.1016/S2352-3018(19)30338-8). Against that, the JAMA trial caught a real transient signal: fasting glucose up 7 mg/dL versus placebo at two weeks, gone by six months (DOI 10.1001/jama.2014.8334).

“Do a cycle, keep the results.”

No. This is the single best-answered question about tesamorelin, because the phase 3 extension phases were designed to answer it by re-randomizing responders to continue or stop. In the label's own extension table, patients switched from tesamorelin to placebo for weeks 26–52 regained 25 cm² and 24 cm² of visceral fat in the two studies — a +22% and +16% rebound — while those who continued held flat (DailyMed). The published paper puts it bluntly: "though effects on VAT are sustained during treatment for 52 weeks, these effects do not last beyond the duration of treatment" (DOI 10.1097/QAD.0b013e32830a5058). The 2026 meta-analysis reaches the same conclusion in its own plain-language summary: useful "as long as it is continued" (PMID 42538058).

“It's basically a stronger sermorelin — the GHRH peptides are interchangeable.”

They act at the same receptor and are all named together in one line of the WADA Prohibited List, which is where the resemblance ends. Tesamorelin is the full 44-residue GRF sequence with an N-terminal trans-3-hexenoyl group that blocks DPP-IV cleavage (DOI 10.1111/j.1742-7843.2007.00008.x); sermorelin is the unmodified 1–29 fragment. Only tesamorelin holds a current FDA approval, and it is the only member of the class with two positive phase 3 trials. Interchangeability fails even within the brand: FDA labeling states that EGRIFTA WR and EGRIFTA SV "are not substitutable," because the two are formulated at different strengths and are not milligram-for-milligram equivalent — a smaller quantity of the F8 formulation is bioequivalent to a larger quantity of the older one (the label strengths are in) (DailyMed). If two formulations of the same molecule from the same manufacturer are not substitutable, two different molecules are not either.

“It builds muscle.”

It adds a small, real amount of lean mass and has never been shown to add strength or performance. The label reports mean lean body mass increases of 1.3 kg and 1.2 kg at 26 weeks versus −0.2 kg and −0.03 kg on placebo; the 2026 meta-analysis pools this at +1.42 kg (95% CI 1.13 to 1.71) (DOI 10.1016/j.orcp.2026.01.002). A separate analysis found reduced muscle fat and increased muscle area in adults with HIV (PMID 31237318). But some of a GH-mediated lean-mass gain is water — fluid retention is a labeled warning — and no trial has measured strength, power, or athletic performance on tesamorelin in any population. A trial in COPD-related muscle wasting was terminated after enrolling three patients, for what the registry records as "a non-safety related corporate decision" (NCT01388920).

“Compounded tesamorelin from a peptide clinic is the same drug.”

Chemically it may be; evidentially and legally it is not the same product. Tesamorelin is the component of an approved drug, not a Category 2 bulk substance — it does not appear on FDA's list of bulk drug substances that "may present significant safety risks," which names GHRP-2, GHRP-6, ibutamoren mesylate, ipamorelin acetate and kisspeptin-10 among peptides but not tesamorelin (FDA, updated 2026-04-22). A law-firm client alert summarizing FDA's standing position states that compounding "regularly or in inordinate amounts, a drug product that is essentially a copy of a commercially available drug product is impermissible" (Foley & Lardner client alert, 2026-05). ⚠️ Sourcing note — not T1, and not shippable as it stands. Under R-C, T1 covers peer-reviewed literature and regulator documents. A law-firm client alert is neither: it is a secondary characterization by a private firm, and no primary FDA guidance document is linked anywhere in this file for the "essentially a copy" position. It was previously carried in this file as "FDA guidance, summarized," which was wrong about its tier as well as its author. It is reported here as what it is, and must be replaced with the underlying FDA guidance before publication. Separately, ECRI and ISMP's 2026 white paper on compounded peptide products states that patients using such products "have no source of reliable information about whether they work or whether they are safe" — a statement about the compounded wellness-peptide market generally; tesamorelin is not named in that document, and we do not attribute its findings to tesamorelin here (ECRI/ISMP, 2026).

“The cancer risk is theoretical hand-waving.”

It is not hand-waving, and it is also not a documented signal. The label makes active malignancy an outright contraindication, requires any preexisting malignancy to be inactive and its treatment complete before starting, and directs discontinuation "if there is any evidence of recurrent malignancy" — on the stated mechanistic ground that tesamorelin "induces the release of endogenous growth hormone (GH), a known growth factor." It also states that "the effects of prolonged elevations in IGF-1 levels are unknown," that 47% of patients exceeded 2 SD scores and 36% exceeded 3 SDS for IGF-1 by 26 weeks, and that life-time carcinogenicity studies in rodents have not been conducted with tesamorelin acetate (DailyMed). No trial has reported an excess of malignancy; no trial was long enough or large enough to detect one. This is an open question with a labeled precaution attached, not a resolved one in either direction. ---

Who it's for, who should skip

FDA-approved (Egrifta) for HIV-associated lipodystrophy; body-composition/longevity use is off-label physician discretion, extrapolated from that indication. Not for anyone with active or recent cancer, or who is pregnant.

Skip it if

  • active or recent cancer — GH-axis stimulation can promote tumor growth. hard block
  • pregnancy — Contraindicated in pregnancy. hard block

Running it

Form
injectable
Dose
daily subcutaneous injection (approved HIV-lipodystrophy indication)
Titration
no standardized protocol for off-label body-composition use; physician-directed

What to expect

  • First days–2 weeks — IGF-1 rises; in a healthy-men study IGF-1 increased 181 µg/L over two weeks with GH pulse area and basal secretion both up. In the JAMA trial, fasting glucose rose 7 mg/dL versus placebo at week 2 and was no longer significant later (Confidence: Trial-documented (DOI 10.1210/jc.2010-1587; DOI 10.1001/jama.2014.8334))
  • ~13 weeks — Label records IGF-1 exceeding 2 SD scores in 47% and 3 SDS in 36% of patients, "with this effect seen as early as 13 weeks" (Confidence: Trial-documented (DailyMed))
  • 3 months — A predictors analysis of the pooled phase 3 data found no factors predictive of VAT response at 3 months — the 3-month mark did not distinguish responders from non-responders (Confidence: Trial-documented (PMID 26457580))
  • 6 months — The primary endpoint window. VAT −18% and −14% in the two phase 3 trials; triglycerides down; trunk fat down ~1 kg; lean body mass up ~1.2–1.3 kg; body weight essentially unchanged. Roughly 70% of participants in the pooled trials met the ≥8% VAT-reduction responder threshold (Confidence: Trial-documented (DailyMed; PMID 33756511))
  • 12 months — Reduction maintained rather than deepened: VAT −17.5% at week 52 in continuers, i.e. approximately the 26-week effect held flat. In HIV-associated NAFLD, 12 months produced a −37% relative reduction in liver fat (Confidence: Trial-documented (DOI 10.1210/jc.2010-0490; DOI 10.1016/S2352-3018(19)30338-8))
  • On stopping — Visceral fat re-accumulates. Re-randomized switchers gained back 25 cm² and 24 cm² over the following 26 weeks (+22%, +16%), while continuers stayed flat (Confidence: Trial-documented — this is the best-answered question about the compound (DailyMed; DOI 10.1097/QAD.0b013e32830a5058))
  • Anti-drug antibodies — Anti-tesamorelin IgG detected in 50% at 26 weeks and 47% at 52 weeks; ~60% of those cross-reacted with endogenous GHRH; in vitro neutralizing antibodies in 10% at week 52. VAT and IGF-1 responses were comparable with and without antibodies. Of those antibody-positive at 26 weeks and retested 6 months after stopping, 18% remained positive (Confidence: Trial-documented (DailyMed))
  • Beyond ~18 months — Not characterized. The longest randomized exposure in the literature is 12 months; the FDA-required long-term observational safety study (NCT01579695) and the retinopathy trial (NCT01591902) were both terminated in 2018 with no reason recorded and no results posted (T2 — registry record, self-asserted) (Confidence: No data)
  • Cardiovascular outcomes — Never studied. Label: "Long-term cardiovascular safety of EGRIFTA WR has not been established." Surrogate improvements (cIMT, CRP, triglycerides) have been documented in a 60-person trial (Confidence: Surrogate only (DOI 10.1210/jc.2012-2794))

Response signs

Likely working

  • Waist circumference falling by 2–3 cm while body weight does not change — Trial-documented — this dissociation is the drug's signature; weight change was non-significant while waist fell · DailyMed Trial-documented
  • Self-reported reduction in "belly appearance distress"; improved physician-rated belly profile — Trial-documented — prespecified patient-reported outcomes, significant vs placebo (P=0.002 and P<0.001 pooled) · DOI 10.1210/jc.2010-0490 Trial-documented
  • A rise in measured IGF-1 — Trial-documented — but note this confirms the drug is pharmacologically active, not that visceral fat is falling; the two were not tightly coupled in individuals · DailyMed Trial-documented
  • Falling triglycerides — Trial-documented · DOI 10.1056/NEJMoa072375 Trial-documented
  • "More energy," better sleep, sharper thinking within 2–3 weeks — Anecdotal, low confidence — a common clinic-marketing claim (Secret Med Spa). The one randomized cognition trial ran 20 weeks, not 3, and two follow-up trials failed to confirm it · DOI 10.1093/infdis/jiaf012 Anecdotal

Adverse — seek review

  • Swelling of hands, feet or ankles; puffiness; new joint pain or stiffness — Trial-documented — peripheral edema 6% vs 2%, arthralgia 13% vs 11%, musculoskeletal stiffness 2% vs 0%. The label attributes these to GH-induced fluid retention, "either transient or resolve with discontinuation" · DailyMed Trial-documented
  • Numbness, tingling, or night-time hand pain — the carpal-tunnel pattern — Trial-documented — paresthesia 5% vs 2%, hypoesthesia 4% vs 2%, carpal tunnel syndrome 1% vs 0%; named in the label's Fluid Retention warning. A 2025 pharmacovigilance study specifically examined medication-attributed carpal tunnel syndrome · DailyMed; PMID 40510111 Trial-documented
  • Rising thirst, urination, or a rising HbA1c — Trial-documented — glucose intolerance is a labeled warning, with 5% vs 1% crossing HbA1c ≥6.5% · DailyMed Trial-documented
  • Rash, urticaria, or any systemic allergic reaction — Trial-documented — hypersensitivity reactions occurred in trials; anti-tesamorelin IgG was detected in 85% of the hypersensitivity subgroup. The label directs immediate medical attention and discontinuation if suspected · DailyMed Trial-documented
  • New or changing vision, particularly in someone with diabetes — Labeled precaution, not a documented trial signal; the trial designed to answer it was terminated · DailyMed; NCT01591902
  • Any new lump, mass, or symptom suggesting recurrence of a prior malignancy — Labeled contraindication and discontinuation criterion, on mechanistic grounds — not a documented excess in trials · DailyMed

Common / neutral

  • Injection-site redness, itching, pain or bruising — Trial-documented — the label's Warnings section states the incidence was 25% on drug vs 14% on placebo over the first 26 weeks. ⚠️ The label's own adverse-reaction table reports the grouped term "injection site reaction" at 17% vs 6%; the two figures in the same document do not match and we do not resolve them · DailyMed Trial-documented
  • Muscle aches, pain in a limb — Trial-documented — myalgia 6% vs 2%, pain in extremity 6% vs 5% · DailyMed Trial-documented
  • Night sweats, palpitations — Trial-documented, low incidence — each 1% vs 0% · DailyMed Trial-documented
  • The scale not moving — Expected, trial-documented — the drug is weight neutral by label and by trial data. Absence of weight loss is not absence of effect · DailyMed Trial-documented
  • Roughly one person in three not responding — Trial-documented — approximately 70% of pooled phase 3 participants met the ≥8% VAT-reduction responder threshold, meaning about 30% did not; the label directs reconsidering continuation in patients without a VAT reduction · PMID 33756511; DailyMed Trial-documented

Getting it right

  • Monitoring: IGF-1 is monitored during therapy, not merely measured once. The label directs considering discontinuation in patients with persistent elevations — it names >3 SD scores as an example — "particularly if the efficacy response is not robust." In the trials, 36% of patients exceeded 3 SDS by 26 weeks, so this is a common decision point rather than a rare one. mitigate side effect
  • Monitoring: Glucose status is evaluated before initiating and monitored periodically thereafter, to identify patients who develop impaired glucose tolerance or diabetes. Where that happens, the label directs considering discontinuation in patients without a clear efficacy response. mitigate side effect
  • Monitoring: Patients with diabetes are monitored at regular intervals for development or worsening of retinopathy. mitigate side effect
  • Monitoring: Visceral adipose tissue response is itself a monitored endpoint. The Limitations of Use direct clinicians to "consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue." In practice that means the drug carries a built-in stopping rule, which most compounds in this batch do not. mitigate side effect
  • Monitoring: Imaging in the trials was CT at the L4–L5 level; the off-label literature used MRI and proton magnetic resonance spectroscopy for liver fat. A DXA-versus-CT comparison study exists and found the two methods are not interchangeable for visceral fat (PMID 30804324) — relevant to anyone interpreting a body-composition scan as a response measure. mitigate side effect
  • General safety: Four absolute contraindications are stated on the label: disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, head trauma); active malignancy; known hypersensitivity to tesamorelin or excipients; and pregnancy. mitigate side effect
  • General safety: Any preexisting malignancy must be inactive and its treatment complete before therapy begins, and the label directs discontinuation on any evidence of recurrence. mitigate side effect
  • General safety: Discontinuation is on the table for critical illness. The label carries the growth-hormone class warning about increased mortality in patients with acute critical illness after open-heart or abdominal surgery, multiple trauma, or acute respiratory failure. mitigate side effect
  • General safety: Drug interactions are documented rather than assumed. Co-administration with simvastatin did not meaningfully change simvastatin pharmacokinetics in healthy subjects, but the label directs monitoring for interactions with CYP450-metabolized drugs, and notes that patients on glucocorticoid replacement for hypoadrenalism may need dose adjustment (PMID 27121785). mitigate side effect
  • General safety: Formulations are not interchangeable. EGRIFTA WR and EGRIFTA SV have different strengths, different reconstitution instructions and different storage requirements, and the labeling states plainly that they "are not substitutable." mitigate side effect
  • General safety: Half of treated patients develop anti-drug antibodies, without loss of VAT or IGF-1 response — but 85% of the hypersensitivity subgroup were antibody-positive, which is the practical reason a rash on this drug is worth reporting rather than tolerating. mitigate side effect
  • General safety: Athletes and service members face strict liability. See. mitigate side effect
  • The physician conversation: Which population am I actually in — the approved indication, one of the studied off-label populations (documented low GH secretion, hepatic steatosis), or neither? ('s absence note.) mitigate side effect
  • The physician conversation: Has visceral adipose tissue actually been measured, by what method, and what is the baseline number? Without it there is no way to apply the label's own continuation rule. mitigate side effect
  • The physician conversation: What are my baseline IGF-1, fasting glucose and HbA1c, and at what values would we stop? (.) mitigate side effect
  • The physician conversation: What is my personal and family history of malignancy, and has anything been treated? (Active malignancy is a contraindication, not a caution.) mitigate side effect
  • The physician conversation: What happens when we stop — and is the plan indefinite therapy? (: the visceral fat comes back.) mitigate side effect
  • The physician conversation: Is this the FDA-approved product or a compounded preparation, and what is the difference in what is known about it? (.) mitigate side effect
  • The physician conversation: Am I subject to any anti-doping or military testing obligation? (— tesamorelin is named on the WADA list.) mitigate side effect

Measuring it

Retest IGF-1 — Baseline, then on a clinician-set schedule — no guideline sets an IGF-1 interval for this agent, and the rhGH cadence is not borrowed..

  • IGF-1 baseline
  • IGF-1 on cycle
  • Fasting glucose baseline
  • Fasting glucose on cycle
  • HbA1c baseline
  • HbA1c quarterly

How biomarkers respond

  • HbA1c May deteriorate · Within 26 weeks — ↑ 5% of tesamorelin patients vs 1% of placebo; hazard ratio 3.3 (CI 1.4, 9.6) from a mean baseline of 5.3% — Trial-documented, per FDA label — ⚠️ and in direct tension with the published papers' "no significant change in glycemic measures." Both reported. (DailyMed vs DOI 10.1056/NEJMoa072375) Trial-documented
  • Fasting glucose May deteriorate · 2 weeks (transient) — ↑ +7 mg/dL vs placebo at week 2, not significant at 6 months — Trial-documented (n=50 RCT) (DOI 10.1001/jama.2014.8334) Trial-documented
  • Fasting insulin May deteriorate · 20 weeks — ↑ 35% within the normal range in the MCI subgroup only, not in healthy older adults — Trial-documented (DOI 10.1001/archneurol.2012.1970) Trial-documented
  • IGF-1 May deteriorate · From 13 weeks — ↑ 47% exceeded 2 SDS and 36% exceeded 3 SDS by 26 weeks. Label: "the effects of prolonged elevations in IGF-1 levels are unknown"; directs monitoring and considering discontinuation at persistent >3 SDS — Trial-documented; consequence undetermined (DailyMed) Trial-documented
  • TSH May deteriorate · Across the trial program — No clinically significant change — a genuine point of difference from the older GH-releasing peptides — Trial-documented negative (DailyMed) Trial-documented

Safety

  • injection-site reactions, peripheral edema, carpal-tunnel-like symptoms from elevated IGF-1

Stacking & alternatives

  • Complements CJC-1295 — Marketed as combinations. No combination containing tesamorelin has ever been tested against tesamorelin alone in any population
  • Complements Ipamorelin — Marketed as combinations. No combination containing tesamorelin has ever been tested against tesamorelin alone in any population
  • Complements Sermorelin — Marketed as combinations. No combination containing tesamorelin has ever been tested against tesamorelin alone in any population

Access & cost

Prescription or clinician order — typically via physician (off-label prescribing).

A lawful channel exists, so this section reports real prices. Tesamorelin is available in the US only as a prescription brand product; there is no generic and, as a product now regulated as a biologic, no approved biosimilar. EGRIFTA WR (tesamorelin F8) — 11.6 mg kit — four single-patient-use vials, each reconstituted weekly, i.e. ~28 days' supply — from $10,708.84 per kit — Drugs.com price guide EGRIFTA (original 1 mg/vial formulation) — 60 vials — $6,040.69 (~$100.68/vial) — Drugs.com price guide EGRIFTA (2 mg presentation) — 30 vials — $2,610.13 (~$87.00/vial) — Drugs.com price guide > On the strengths in the Presentation column. The 11.6 mg kit, the 1 mg vial and the 2 mg vial are product presentations — the nominated vial strengths of the approved product as the price record lists them. They are kept here as regulatory formulation records, not as exposures: no daily quantity, schedule or per-dose amount is stated in this section, and the label regimen itself lives in. At the EGRIFTA WR cash price, a month of the approved product is roughly $10,700, or on the order of $128,000 a year if taken continuously — and establishes that the effect does not persist after stopping, so continuous use is the modelled scenario rather than a course. Discount-card pricing quoted publicly for the same kit runs to $44,179.95 on a GoodRx coupon, which the site describes as up to 80% off average retail (GoodRx) — a figure that only makes sense against a multi-kit quantity and which we report as quoted rather than reconcile. Almost nobody pays those numbers. The manufacturer runs a co-pay assistance program (THERA Patient Support) for commercially insured patients, and the drug is typically dispensed through specialty pharmacy with prior authorization tied to the HIV-lipodystrophy indication (Drugs.com). The practical consequence for anyone outside that indication is direct: off-label use is cash-pay at the brand price, which is the economic reason a compounded market exists at all. Compounded and non-brand supply. A market in non-brand tesamorelin exists and is openly advertised by wellness clinics and peptide sellers, which is why the compounded question is answered on evidence in rather than ignored here. No INTERNAL subsection is included for this compound: Ruling 4 confines specific gray-market figures to journalist-reported sources, and no such reporting specific to tesamorelin pricing was located. The figures circulating for compounded tesamorelin come from sellers and marketing sites, which this file does not treat as price evidence and does not name. ---

Questions

Does tesamorelin actually work?
For its approved purpose, yes, and the evidence is unusually good for this batch: two randomized, double-blind, placebo-controlled phase 3 trials totaling 806 patients, both hitting a CT-imaged primary endpoint, with concordant 2026 meta-analyses (DOI 10.1210/jc.2010-0490; DOI 10.1016/j.orcp.2026.01.002). "Works" means roughly a 15% reduction in visceral adipose tissue in people with HIV-associated fat redistribution — not weight loss, and not in a population that has ever been studied outside HIV, low-GH obesity, hepatic steatosis or age-related cognitive concern.
Will it make me lose weight?
No, and the label says so: tesamorelin "is not indicated for weight loss management as it has a weight neutral effect." The phase 3 trials recorded mean weight changes of −0.4 kg and +0.5 kg against placebo differences that crossed zero, at the same time as visceral fat fell 14–18% (DailyMed). It redistributes rather than subtracts.
How long until it works?
The trials measured at 3 and 6 months, and 6 months was the endpoint. A formal predictors analysis found nothing at 3 months that identified who would respond (PMID 26457580). IGF-1 moves much sooner — by 13 weeks a majority of trial patients were above 2 SD scores (DailyMed). Marketing claims of "noticeable abdominal fat reduction within 4–8 weeks" (Secret Med Spa, cited as a claim) run ahead of any trial measurement.
What happens when you stop?
Visceral fat comes back. This was measured directly by re-randomizing patients to placebo at week 26; they regained 25 cm² and 24 cm² over the next six months while continuers held flat (DOI 10.1097/QAD.0b013e32830a5058).
Does tesamorelin cause diabetes?
This is the one question where the trial papers and the FDA label do not agree, and both are printed in. Mean glucose, insulin and HbA1c did not shift in the trials; the label reports 5% versus 1% of patients crossing HbA1c ≥6.5% with a hazard ratio of 3.3 (CI 1.4, 9.6) and lists glucose intolerance as a warning requiring glucose evaluation before and during therapy (DailyMed). A dedicated trial in people who already had type 2 diabetes found no worsening over 12 weeks (DOI 10.1371/journal.pone.0179538).
Is there an oral or nasal version?
Not one with evidence. Every human efficacy trial and both current FDA labels use daily subcutaneous injection into the abdomen. The only non-injectable route ever published for this molecule is a pulmonary delivery study in dogs (PMID 15113616) — an animal formulation experiment, never followed into humans. Absolute subcutaneous bioavailability was measured at under 4% in healthy adults (DailyMed); a 5,136-dalton peptide with that little bioavailability by injection has no plausible oral route without a delivery technology nobody has published for it. Treat any oral or nasal tesamorelin claim as unsupported.
Is it safe?
Better characterized than anything else in this batch, and not unqualified. 740 patients received tesamorelin in the registration trials. Adverse reactions more frequent than placebo at ≥1% over 26 weeks included arthralgia (13% vs 11%), pain in extremity (6% vs 5%), myalgia (6% vs 2%), peripheral edema (6% vs 2%), paresthesia (5% vs 2%), hypoesthesia (4% vs 2%) and rash (4% vs 2%). Contraindications are active malignancy, disrupted hypothalamic-pituitary axis, hypersensitivity, and pregnancy (DailyMed). Half of treated patients developed anti-drug antibodies, without loss of effect. The two long-term safety studies FDA required at approval were terminated in 2018 without published results.
Does it help fatty liver?
In people with HIV, the randomized answer is yes: a 12-month multicentre trial found a −4.1 percentage-point absolute reduction in hepatic fat fraction versus placebo, with 35% versus 4% dropping below the 5% steatosis threshold (DOI 10.1016/S2352-3018(19)30338-8). Outside HIV this has never been tested; the drug is not approved for liver disease anywhere.
Does it improve memory?
One randomized trial says maybe, two follow-ups did not confirm it. Baker et al. found a favorable 20-week effect on cognition, strongest for executive function (DOI 10.1001/archneurol.2012.1970). A 73-person open-label trial in people with HIV found no significant difference versus standard of care (DOI 10.1093/infdis/jiaf012), and a 22-person pilot found no significant change on any prespecified measure (DOI 10.1016/j.ensci.2026.100616). Nobody has run a trial long enough to speak to dementia risk. ---

Last reviewed 27 August 2026. Regulatory status verified 27 August 2026.